JP6666254B2 - アンドロゲン受容体アンタゴニストの固体医薬組成物 - Google Patents

アンドロゲン受容体アンタゴニストの固体医薬組成物 Download PDF

Info

Publication number
JP6666254B2
JP6666254B2 JP2016550203A JP2016550203A JP6666254B2 JP 6666254 B2 JP6666254 B2 JP 6666254B2 JP 2016550203 A JP2016550203 A JP 2016550203A JP 2016550203 A JP2016550203 A JP 2016550203A JP 6666254 B2 JP6666254 B2 JP 6666254B2
Authority
JP
Japan
Prior art keywords
enzalutamide
solid
arn
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016550203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507928A (ja
JP2017507928A5 (cg-RX-API-DMAC7.html
Inventor
フラヘク，ロク
レバー，アンドリヤ
ドラクスラー，ペトラ
ペテク，ボスジャン
オパラ，イェルネヤ
ナベルスニク，クレメン
ボジチ，ペトラ
Original Assignee
レツク・フアーマシユーテイカルズ・デー・デー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レツク・フアーマシユーテイカルズ・デー・デー filed Critical レツク・フアーマシユーテイカルズ・デー・デー
Publication of JP2017507928A publication Critical patent/JP2017507928A/ja
Publication of JP2017507928A5 publication Critical patent/JP2017507928A5/ja
Priority to JP2019238913A priority Critical patent/JP6934932B2/ja
Application granted granted Critical
Publication of JP6666254B2 publication Critical patent/JP6666254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016550203A 2014-02-05 2015-02-04 アンドロゲン受容体アンタゴニストの固体医薬組成物 Expired - Fee Related JP6666254B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019238913A JP6934932B2 (ja) 2014-02-05 2019-12-27 アンドロゲン受容体アンタゴニストの固体医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14154047.6 2014-02-05
EP14154047 2014-02-05
PCT/EP2015/052311 WO2015118015A1 (en) 2014-02-05 2015-02-04 Solid pharmaceutical compositions of androgen receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019238913A Division JP6934932B2 (ja) 2014-02-05 2019-12-27 アンドロゲン受容体アンタゴニストの固体医薬組成物

Publications (3)

Publication Number Publication Date
JP2017507928A JP2017507928A (ja) 2017-03-23
JP2017507928A5 JP2017507928A5 (cg-RX-API-DMAC7.html) 2018-03-08
JP6666254B2 true JP6666254B2 (ja) 2020-03-13

Family

ID=50031275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016550203A Expired - Fee Related JP6666254B2 (ja) 2014-02-05 2015-02-04 アンドロゲン受容体アンタゴニストの固体医薬組成物
JP2019238913A Expired - Fee Related JP6934932B2 (ja) 2014-02-05 2019-12-27 アンドロゲン受容体アンタゴニストの固体医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019238913A Expired - Fee Related JP6934932B2 (ja) 2014-02-05 2019-12-27 アンドロゲン受容体アンタゴニストの固体医薬組成物

Country Status (10)

Country Link
US (2) US20160346207A1 (cg-RX-API-DMAC7.html)
EP (1) EP3102183A1 (cg-RX-API-DMAC7.html)
JP (2) JP6666254B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160113294A (cg-RX-API-DMAC7.html)
CN (2) CN112402360A (cg-RX-API-DMAC7.html)
AU (1) AU2015215000B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940984A1 (cg-RX-API-DMAC7.html)
EA (2) EA037895B1 (cg-RX-API-DMAC7.html)
MX (1) MX386859B (cg-RX-API-DMAC7.html)
WO (1) WO2015118015A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
PL3226843T3 (pl) * 2014-12-05 2021-12-13 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
CN114886852A (zh) 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
CA2969661C (en) * 2014-12-05 2023-04-25 Aragon Pharmaceuticals, Inc. Anticancer compositions
MX2018014846A (es) * 2016-06-03 2019-03-14 Aragon Pharmaceuticals Inc Composiciones antineoplasicas.
WO2017221144A1 (en) * 2016-06-20 2017-12-28 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
EP3500310A1 (en) 2016-08-20 2019-06-26 FTF Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
KR102684756B1 (ko) * 2017-04-28 2024-07-15 아스텔라스세이야쿠 가부시키가이샤 엔잘루타미드를 함유하는 경구 투여용 의약 조성물
WO2019008426A1 (en) * 2017-07-04 2019-01-10 Bdr Pharmaceuticals International Private Limited NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
RU2020109948A (ru) * 2017-08-08 2021-09-10 Др. Редди'З Лабораториз Лимитед Экструдированные композиции энзалутамида
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108815129A (zh) * 2018-07-12 2018-11-16 天津双硕医药科技有限公司 一种恩杂鲁胺纳米晶体口服固体药物组合物
ES2943492T3 (es) 2018-11-30 2023-06-13 Chemocentryx Inc Formulación de cápsulas
JP2022533463A (ja) * 2019-05-23 2022-07-22 ヘルム・アクチエンゲゼルシャフト エンザルタミドを含むナノ粒子
EP4037659B1 (en) 2019-10-03 2025-11-19 Synthon BV Pharmaceutical composition comprising enzalutamide
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
US20240207239A1 (en) * 2021-02-06 2024-06-27 Sunshine Lake Pharma Co., Ltd. Composition and preparation method therefor
WO2024127361A1 (en) 2022-12-16 2024-06-20 Ferring B.V. Enzalutamide nanocrystals, methods and compositions
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448825C (en) * 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
CN102755318B (zh) * 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
US9108944B2 (en) * 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2877599B1 (en) * 2012-07-27 2019-10-23 Aragon Pharmaceuticals, Inc. Methods and compositions for determining resistance to androgen receptor therapy
DK3725778T3 (da) * 2012-09-11 2021-09-20 Medivation Prostate Therapeutics Llc Formuleringer af enzalutamid

Also Published As

Publication number Publication date
AU2015215000B2 (en) 2017-10-19
EA201691568A1 (ru) 2017-01-30
EA201891397A1 (ru) 2019-03-29
MX2016010216A (es) 2016-11-15
KR20200015830A (ko) 2020-02-12
JP2017507928A (ja) 2017-03-23
CN112402360A (zh) 2021-02-26
AU2015215000A1 (en) 2016-09-15
CA2940984A1 (en) 2015-08-13
US20160346207A1 (en) 2016-12-01
JP6934932B2 (ja) 2021-09-15
MX386859B (es) 2025-03-19
CN106102716A (zh) 2016-11-09
JP2020090505A (ja) 2020-06-11
EP3102183A1 (en) 2016-12-14
WO2015118015A1 (en) 2015-08-13
US20200163882A1 (en) 2020-05-28
EA037895B1 (ru) 2021-06-02
KR20160113294A (ko) 2016-09-28

Similar Documents

Publication Publication Date Title
JP6666254B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
JP3696087B2 (ja) イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
JP2018184410A (ja) 非晶質ダパグリフロジンを含有する製剤
CA2691752A1 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
WO2008027600A2 (en) Imatinib compositions
WO2011140446A2 (en) Pharmaceutical formulations
CA2903440A1 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
JP2015500853A (ja) 即時放出マルチユニットペレットシステム
JP2022185033A (ja) プロトンポンプ阻害剤を含む経口用固形製剤組成物、それを含む経口用固形製剤及びその製造方法
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
CN104254321A (zh) 稳定性提高的药物制剂
AU2017339246B2 (en) Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
WO2016102661A1 (en) Pharmaceutical tablet composition
JP7264711B2 (ja) レベチラセタム含有医薬組成物の製造方法
KR101845665B1 (ko) 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
JP4342426B2 (ja) イトラコナゾール経口投与用製剤
US20120121700A1 (en) Pharmaceutical formulations comprising valganciclovir
HK40066406B (zh) 肠溶微丸、其制备方法和包含它的制剂
HK40066406A (zh) 肠溶微丸、其制备方法和包含它的制剂
HK40066405A (zh) 肠溶微丸、其制备方法和包含它的制剂
HK40066405B (zh) 肠溶微丸、其制备方法和包含它的制剂
WO2019132840A1 (en) A pharmaceutical formulation for oral administration comprising dabigatran etexilate
JP2006315971A (ja) イトラコナゾール経口投与製剤
HU226952B1 (hu) Klopidogrel-hidrogénszulfát szilárd diszperziója, az ezt tartalmazó gyógyszerkészítmények és eljárás elõállításukra

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200114

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200220

R150 Certificate of patent or registration of utility model

Ref document number: 6666254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees